Survey of Adverse Events and Continuity of Treatment in Old-Old Patients Treated With Trifluridine / Tipiracil Hydrochloride for Colorectal Cancer
- VernacularTitle:後期高齢者の結腸・直腸がんに対するトリフルリジン・チピラシル塩酸塩療法の有害事象発現状況と治療継続状況に関する実態調査
- Author:
Mai YOSHIIKE
1
;
Tomoaki MIYATA
1
;
Ayano HARA
1
;
Masahide SUGIYAMA
1
;
Keisuke SHINOHARA
1
;
Hirotaka SEKIGUCHI
1
;
Daiji SEKIDO
1
Author Information
- From:Journal of the Japanese Association of Rural Medicine 2021;70(4):360-365
- CountryJapan
- Language:Japanese
- Abstract: Trifluridine (FTD) / tipiracil hydrochloride (TPI) has been approved for the treatment of colorectal cancer, but its dose-limiting toxicity is neutropenia. Elderly patients are at high risk of febrile neutropenia and should be monitored carefully when administering FTD / TPI. In this study, we retrospectively investigated the incidence of adverse events, dose reduction, and number of administered courses in 8 old-old patients treated with FTD / TPI for colorectal cancer. The results showed that severe neutropenia of Grade 3 or higher occurred in 5 of the 8 patients. Six patients had a dose reduction, but 5 of them were able to continue treatment for at least 3 courses. The frequency and severity of adverse events, including neutropenia, appears to be higher in old-old patients, so it is important to take appropriate measures.
